m+Medelevator.RU
← Поиск публикаций
Frontiers in cellular and infection microbiology · 2026

Isolation and characterization of a novel Staphylococcus phage SPD: genomic insights and its anti-biofilm efficacy against methicillin-resistant Staphylococcus aureus.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zheng Xiaofeng, Ma Lan, Li Yongchao, Liu Bo, Zhang Wei, Su Xiaoyue, Liu Yingyu

Аннотация

OBJECTIVE: To isolate and characterize a novel Staphylococcus phage with activity against animal-derived methicillin-resistant Staphylococcus aureus (MRSA) infections and biofilms in Kashgar, Xinjiang.

METHODS: Phage SPD was isolated through enrichment from farm wastewater, purified using the double-layer plaque assay, and characterized by using transmission electron microscopy (TEM), spot assays, growth kinetics, stability tests, and whole-genome sequencing (Illumina HiSeq). Anti-biofilm activity was evaluated via crystal violet staining.

RESULTS: SPD is a virulent Podovirus characterized by an icosahedral head (~50 nm in diameter) and a short tail phage (~60 nm in length). It exhibits a broad host range (lyses 38 out of 50 tested strains, including 7 MRSA), a short latent period (~10 min), a high burst size (4,470 PFU/cell), and stability at temperatures ranging from 4 to 50 °C and pH values between 6 and 9. The 17,066 bp double-stranded DNA genome (35.1% GC content) encodes a lysin and a holin, with no virulence or antibiotic resistance genes detected. SPD effectively inhibits planktonic MRSA growth and reduces biofilm formation (>50% inhibition) as well as pre-formed biofilms (>60% clearance) in vitro.

CONCLUSION: SPD represents a safe, novel Andhravirus phage with potent activity against MRSA and biofilms, offering a promising candidate for phage therapy, particularly in the Xinjiang region.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты